Carregant...
Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
Chimeric antigen receptor (CAR) T cell therapy, together with checkpoint inhibition, has been celebrated as a breakthrough technology due to the substantial benefit observed in clinical trials with patients suffering from relapsed or refractory B‐cell malignancies. In this review, we provide a compr...
Guardat en:
| Publicat a: | EMBO Mol Med |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5582407/ https://ncbi.nlm.nih.gov/pubmed/28765140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201607485 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|